Challenges facing the development of the industry

Technology and process iteration is fast

Pharmaceutical intermediates industry is a technology-intensive industry, product update speed, a product is generally on the market 3 to 5 years later, its profit margin will be significantly reduced, the company's ability to expand business depends largely on the success of research and development activities, which forces enterprises must continue to develop new products or improve the production process, in order to maintain a high production profit.

Environmental protection requirements are increasingly stringent

With the rapid development of the economy in our country, environmental pollution is increasingly serious. In recent years, the state attaches more and more importance to environmental protection, and has introduced a series of policies and regulations to promote the development of environmental protection industry. Under this situation, the construction of ecological civilization has risen to the national strategic height. The discussion about the relationship between environmental protection and economy is becoming more and more intense. The production process of the industry involves a variety of complex chemical reactions, and then produces waste water, waste gas, solid waste (collectively referred to as the "three wastes") and other polluting emissions, if not properly treated, will have a certain adverse impact on the surrounding environment.

The financial strength of some enterprises in the pharmaceutical intermediates industry is weak

The development and technological progress of pharmaceutical intermediates industry require a large amount of R&D investment, whether it is new technology, new product development and transformation, all need financial support, but in addition to a few large enterprises lay industry enterprises are mostly small and medium-sized enterprises, there is a certain shortage in financial strength, and its main source of funds for their own business accumulation and bank loans. There are certain deficiencies in the scale and source channels of funds, which limit the scientific and technological innovation of enterprises in the industry.